CN1676163A - Human glucagon-like peptide-1 compound and its preparing method - Google Patents
Human glucagon-like peptide-1 compound and its preparing method Download PDFInfo
- Publication number
- CN1676163A CN1676163A CN 200410066897 CN200410066897A CN1676163A CN 1676163 A CN1676163 A CN 1676163A CN 200410066897 CN200410066897 CN 200410066897 CN 200410066897 A CN200410066897 A CN 200410066897A CN 1676163 A CN1676163 A CN 1676163A
- Authority
- CN
- China
- Prior art keywords
- peptide
- human glucagon
- polyethylene glycol
- mpeg
- methoxy polyethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to a human pancreatic glucagons sample peptide-1 compound and its preparation method. The human pancreatic glucagons sample peptide-1 in said compound is human pancreatic glucagons sample peptide-1(7-37) or human pancreatic glucagons sample peptide-1(7-36)Nh2. Said compound is formed from human pancreatic glucagons sample peptide-1 and monomethoxy polyglycol containing active group activated by succinimide, namely said compound is mPEG-GLP-1.
Description
Technical field
The present invention relates to complex of a kind of human glucagon-like-peptide-1 and preparation method thereof, definitely say, relate to a kind of mono methoxy polyethylene glycol-human glucagon-like-peptide-1, be complex of mPEG-GLP-1 and preparation method thereof, belong to the technical field of peptide or proteinic modification complex and preparation thereof.
Background technology
Diabetes are worldwide diseases, and sickness rate is high, and human health is constituted a serious threat.According to international diabetes study institute (IDI) up-to-date address prediction in 2003, global diabetics has reached 1.94 hundred million people, and according to present growth rate, by 2025, number of patients will reach 3.33 hundred million.China has diabetics more than 4,000 ten thousand, and in early 1980s, China's onset diabetes rate only is 0.67%, and ground sickness rate such as Beijing, Shanghai all surpass 10% now, and this numeral is also continuing increase.According to statistics, the year cost that common diabetics is used for the treatment of is 3726 yuan, and diabetics needs lifelong medication, and the Glucovance of therefore developing high performance cheap has tempting prospect.
(glucagon-like peptide-1 mainly is that molecular weight is about 3.355KD by the polypeptide hormone of a kind of 31 peptides of the L emiocytosis of far-end ileum, colon and rectum GLP-1) to human glucagon-like-peptide-1.The major physiological effect of human glucagon-like-peptide-1 comprises: the release action of (1) glucose dependency pancreotropic hormone.Its mechanism of action be by with the special acceptor interaction on pancreatic beta cell surface, the insulin secretion of glucose induction is significantly increased.(2) secretion of release of stimulating growth chalone and glucagon suppression.(3) suppress parietal cell secretion gastric acid, the emptying that prolongs stomach.(4) increase satiety, appetite-suppressing reduces the picked-up of energy.Based on above-mentioned result of study, human glucagon-like-peptide-1 is expected to become the especially polypeptide drugs of type ii diabetes of treatment diabetes.The promoting insulin secretion of human glucagon-like-peptide-1 depends on the concentration of glucose, hypoglycemia can not take place with its treatment diabetes, shows its good prospects for application aspect diabetes especially type ii diabetes treatment.But human glucagon-like-peptide-1 is a kind of bioactive micro peptide, is easy in vivo be caused biological stability poor by a kind of two special acyltransferase polypeptide peptidase IV (DPP IV) degraded, and the half-life only is 2-3 minute in the body.The very short time can only be kept in the blood drug level peak that the subcutaneous injection human glucagon-like-peptide-1 produces, if be used for treating diabetes, need subcutaneous injection every day 3-4 time brings misery or makes the patient be unwilling to accept to the patient.Therefore press for the long human glucagon-like-peptide-1 product of development biological half-life.
Summary of the invention
First technical problem that the present invention will solve is the complex that proposes a kind of human glucagon-like-peptide-1, and the human glucagon-like-peptide-1 in this complex refers to human glucagon-like-peptide-1 (7-37) or human glucagon-like-peptide-1 (7-36) NH
2This complex by human glucagon-like-peptide-1 with contain mono methoxy polyethylene glycol through the activatory active group of butanimide: mono methoxy polyethylene glycol-propanoic acid butanimide, be mPEG-SPA or divide dendritic mono methoxy polyethylene glycol-succinimide ester, be that mPEG-NHS forms, both link together by the former aminoacid free amine group and the amido link that forms of the latter's butanimide ester bond, and described mono methoxy polyethylene glycol molecular weight is 5～40KD.
Another technical problem that the present invention will solve provides a kind of preparation method of complex of human glucagon-like-peptide-1.The present invention makes above-mentioned technical problem be resolved by the following technical programs.Human glucagon-like-peptide-1 and the mono methoxy polyethylene glycol that contains through the activatory active group of butanimide are carried out the mPEG modification reaction, described mono methoxy polyethylene glycol is mono methoxy polyethylene glycol-propanoic acid butanimide, be mPEG-SPA or divide dendritic mono methoxy polyethylene glycol-succinimide ester, be mPEG-NHS, the former the aminoacid free amine group and the latter's butanimide ester bond is with human glucagon-like-peptide-1 and contain the complex that connects to human glucagon-like-peptide-1 through the mono methoxy polyethylene glycol of the activatory active group of butanimide, be mPEG-GLP-1, described mono methoxy polyethylene glycol molecular weight is 5～40KD.
Now describe technical scheme of the present invention in detail.A kind of preparation method of complex of human glucagon-like-peptide-1 is characterized in that, the concrete operations step is as follows:
The first step, the human glucagon-like-peptide-1 of 1 part of weight is dissolved in the 100mM of 500 parts of weight, in the pH7.4 phosphate buffer, again with the 200mM of 500 parts of weight, pH6.0～9.0 phosphate buffers or boric acid-borate buffer solution are mixed, and human glucagon-like-peptide-1 is human glucagon-like-peptide-1 (7-37);
Second step, the mono methoxy polyethylene glycol of containing that in the solution of the first step, adds 1.5～119.0 parts of weight through the activatory active group of butanimide, evenly mixed, described mono methoxy polyethylene glycol is that molecular weight is mono methoxy polyethylene glycol-propanoic acid butanimide of 5～40KD, be mPEG-SPA or divide dendritic mono methoxy polyethylene glycol-succinimide ester, i.e. mPEG-NHS;
The 3rd goes on foot, and second solution that goes on foot is placed carried out the mPEG modification reaction under 4～40 ℃ 0.5～24 hour;
The 4th step will place-20 ℃ of cessation reactions through the solution that the 3rd step handled, and so far, make the complex crude product solution of human glucagon-like-peptide-1;
The 5th step, the 4th crude product solution 20mM that make of step learns from else's experience, the acetic acid of pH4.2-sodium-acetate buffer dilutes 10 times, last Sepharose FF CM chromatographic column, with the 20mM that contains 0～1MNaCl, pH4.2 acetic acid-sodium-acetate buffer carries out gradient elution, and flow velocity is 0.1～1ml/min, is the elute soln that the absworption peak in centre in 3 absworption peaks is collected at the 280nm place at wavelength;
The 6th step, with the 5th elute soln molecular cut off collected of step is that the MilliporeAmicon Ultra-15 ultrafiltration pipe of 1～5KD is concentrated, lyophilization, obtain the product of 0.2～3.9 part of weight, be the pure product of complex of human glucagon-like-peptide-1, the molecular weight of described product is between 8.355～43.355KD.
The 6th step, described product had the structure that the present invention proposes: by human glucagon-like-peptide-1 with contain through the mono methoxy polyethylene glycol of the activatory active group of butanimide and forms, the amido link of the butanimide ester bond formation of both aminoacid free amine groups by human glucagon-like-peptide-1 and mono methoxy polyethylene glycol links together.
Technical scheme of the present invention is further characterized in that in the first step of above-mentioned preparation method, human glucagon-like-peptide-1 is human glucagon-like-peptide-1 (7-36) NH
2
Human glucagon-like-peptide-1 in the above-mentioned preparation process has the branch of chemosynthesis or genetic engineering preparation.The former can be synthetic by any biotech company; The latter sees that the inventor's application number and title are respectively 200410054397.9 and be entitled as the Chinese invention patent application of " efficiently expressing genetic engineering bacterium and the construction method and the application of human glucagon-like-peptide-1 ".Molecular weight is between mono methoxy polyethylene glycol-propanoic acid butanimide of 5～40KD, i.e. mPEG-SPA or divide dendritic mono methoxy polyethylene glycol-succinimide ester, i.e. and mPEG-NHS, both all can buy from Nektar company.
Advantage of the present invention is: utilize the aminoacid free amine group of human glucagon-like-peptide-1 and the activation butanimide ester bond of mono methoxy polyethylene glycol to react under the physiological status of gentleness, form amido link, thereby make the character of complex of the mono methoxy polyethylene glycol-human glucagon-like-peptide-1 that obtains very stable, be difficult for being hydrolyzed separation; Because the dressing agent mPEG that uses is the linear nontoxic macromolecular compound of high-hydrophilic, after itself and human glucagon-like-peptide-1 stable bond, can form a kind of barrier at the human glucagon-like-peptide-1 molecular surface, make human glucagon-like-peptide-1 be difficult for, thereby improve its biological stability by intravital proteasome degradation; While is owing to the human glucagon-like-peptide-1 molecular weight of modifying through mPEG increases, thereby the prolongation of half-life in vivo, has improved the bioavailability of human glucagon-like-peptide-1.Prepare the complex of human glucagon-like-peptide-1 with this method, method is easy, and raw material is easy to get, and production cost is low.
Description of drawings
Now in conjunction with the accompanying drawings and embodiments content of the present invention is described further.
Fig. 1 is the SDS-PAGE electrophoretogram of the mPEG-GLP-1 (7-37) that makes.The 1st, GLP-1 (7-37) contrast; 2,3 and 4 is respectively that the molecular weight of Different Weight is the mPEG-SPA of 5KD and the reaction result of GLP-1 (7-37).
Fig. 2 is the CM Sepharose FF chromatography purification figure of mPEG-GLP-1 (7-37).Wherein, the 5th, penetrate peak (containing the mPEG-GLP-1 (7-37) that multiple spot is modified); The 6th, mPEG-GLP-1 (7-37) absworption peak that single-point is modified; The 7th, the GLP-1 of unmodified (7-37) absworption peak.
Fig. 3 is the SDS-PAGE electrophoretogram of the pure product of mPEG-GLP-1 (7-37) (not lyophilization).Wherein, the 8th, the mPEG-GLP-1 (7-37) that single-point is modified; The 9th, multiple spot modify mPEG-GLP-1 (7-37).
Fig. 4 is the hypoglycemic activity figure as a result of mPEG-GLP-1 (7-37).The result shows among the figure:
(1) GLP-1 (7-37) with the gene engineering method preparation has kept the hypoglycemic biologic activity of natural GLP-1 (7-37);
(2) kept the hypoglycemic biologic activity of natural GLP-1 (7-37) through the GLP-1 of mPEGization (7-37);
(3) through the hypoglycemic time significant prolongation of the GLP-1 of mPEGization (7-37).
The specific embodiment
Below by specific embodiment, be described in further detail the present invention.Used mPEG, chemical reagent etc. in following examples, and the experimental technique of unreceipted actual conditions are undertaken routinely or by the condition that goods supplier is advised.
The preparation of the complex of embodiment 1 human glucagon-like-peptide-1.In the present embodiment, be the poly-ethanol of mono methoxy-propanoic acid butanimide through the mono methoxy polyethylene glycol of the activatory active group of butanimide, i.e. mPEG-SPA, its molecular weight is 5KD.
The first step is dissolved in the 100mM of 0.5ml with 1.0mg human glucagon-like-peptide-1 (7-37), and is in the pH7.4 phosphate buffer, mixed with 200mM phosphate buffer or the boric acid-borate buffer solution of the pH6.0-9.0 of 0.5ml again;
In second step, adding the 1.5mg molecular weight in the solution of the first step is mono methoxy polyethylene glycol-propanoic acid butanimide of 5KD, and promptly mPEG-SPA is evenly mixed;
The 3rd goes on foot, and second solution that goes on foot gained is placed under 4 ℃～40 ℃ carried out the mPEG modification reaction 0.5～24 hour;
The 4th step will place-20 ℃ of cessation reactions through the solution that the 3rd step handled, and so far, make the complex crude product solution of human glucagon-like-peptide-1 (7-37);
Illustrate: the complex crude product solution of getting 20ul human glucagon-like-peptide-1 (7-37) is carried out the SDS-PAGE electrophoresis, checks the mPEG degree of modification, the results are shown in Figure 1.
The 5th step, the 4th crude product solution 20mM that make of step learns from else's experience, the acetic acid of pH4.2-sodium-acetate buffer dilutes 10 times, last Sepharose FF CM chromatographic column, with the 20mM that contains 0～1MNaCl, pH4.2 acetic acid-sodium-acetate buffer carries out gradient elution, and flow velocity is 0.1～1ml/min, is the elute soln that the absworption peak in centre in 3 absworption peaks is collected at the 280nm place at wavelength;
Illustrate: referring to Fig. 2, among the figure, 5 is first absworption peaks in 3 absworption peaks, promptly penetrates peak (containing mPEG-GLP-1 (7-37) the absorption honeybee that multiple spot is modified); 6 is the absworption peaks in 3 centres in the absworption peak, i.e. mPEG-GLP-1 (7-37) absworption peak of single-point modification; 7 is the 3rd absworption peak in 3 absworption peaks, the i.e. GLP-1 of unmodified (7-37) absworption peak.From the eluent corresponding, respectively get 20ul and carry out the SDS-PAGE electrophoresis, the results are shown in Fig. 3 with absworption peak 5,6, among the figure, the 8th, the mPEG-GLP-1 (7-37) that single-point is modified, the 9th, the mPEG-GLP-1 (7-37) that multiple spot is modified.
The 6th step, with the 5th elute soln molecular cut off collected of step is that the MilliporeAmicon Ultra-15 ultrafiltration pipe of 1～5KD is concentrated, lyophilization, obtain 0.2mg, molecular weight is the pure product of complex of the human glucagon-like-peptide-1 (7-37) of 8.355KD.
In above-mentioned second step, molecular weight is mono methoxy polyethylene glycol-propanoic acid butanimide of 5KD, and promptly the addition of mPEG-SPA can be respectively 7.5mg and 15mg; In above-mentioned the 6th step, can obtain respectively 0.7 and the molecular weight of 0.5mg be the pure product of complex of the human glucagon-like-peptide-1 (7-37) of 8.355KD.
In the first step, with human glucagon-like-peptide-1 (7-36) NH
2Replace human glucagon-like-peptide-1 (7-37), also can obtain being similar to the result in above-mentioned the 6th step.
The preparation of the complex of embodiment 2 human glucagon-like-peptide-1s.In the present embodiment, through the mono methoxy polyethylene glycol of the activatory active group of butanimide for dividing a dendritic mono methoxy polyethylene glycol-succinimide ester, i.e. mPEG-NHS, its molecular weight is 10KD.
The first step is dissolved in the 100mM of 0.5ml with 1.0mg human glucagon-like-peptide-1 (7-37), and is in the pH7.4 phosphate buffer, mixed with the 200mM phosphate buffer or the boric acid-borate buffer solution of pH6.0～9.0 of 0.5ml again;
In second step, adding the 3.0mg molecular weight in the solution of the first step is the dendritic mono methoxy polyethylene glycol-succinimide ester of branch of 10KD, and promptly mPEG-NHS is evenly mixed;
The 3rd step to the 5th step is undertaken by cycle and taking corresponding operation among the embodiment one.
The 6th step, with the 5th elute soln molecular cut off collected of step is that the MilliporeAmicon Ultra-15 ultrafiltration pipe of 1～5KD is concentrated, lyophilization, obtain 0.4mg, molecular weight is the pure product of complex of the human glucagon-like-peptide-1 (7-37) of 13.355KD.
In above-mentioned second step, molecular weight is the dendritic mono methoxy polyethylene glycol-succinimide ester of the branch of 10KD, and promptly the addition of mPEG-NHS can be respectively 15.0mg and 30.0mg; In above-mentioned the 6th step, can obtain respectively 1.2 and the molecular weight of 0.8mg be the pure product of complex of the human glucagon-like-peptide-1 (7-37) of 13.355KD.
In the first step, with human glucagon-like-peptide-1 (7-36) NH
2Replace human glucagon-like-peptide-1 (7-37), also can obtain being similar to the result in above-mentioned the 6th step.
The preparation of the complex of embodiment 3 human glucagon-like-peptide-1s.In the present embodiment, be mono methoxy polyethylene glycol-propanoic acid butanimide through the mono methoxy polyethylene glycol of the activatory active group of butanimide, i.e. mPEG-SPA, its molecular weight is 20KD.
The first step is dissolved in the 100mM of 0.5ml with 1.0mg human glucagon-like-peptide-1 (7-37), and is in the pH7.4 phosphate buffer, mixed with 200mM phosphate buffer or the boric acid-borate buffer solution of the pH8.4 of 0.5ml again;
In second step, adding the 6.0mg molecular weight in the solution of the first step is mono methoxy polyethylene glycol-propanoic acid butanimide of 20KD, and promptly mPEG-SPA is evenly mixed;
The 3rd step to the 5th step is undertaken by cycle and taking corresponding operation among the embodiment one.
The 6th step, with the 5th elute soln molecular cut off collected of step is that the MilliporeAmicon Ultra-15 ultrafiltration pipe of 1～5KD is concentrated, lyophilization, obtain 0.7mg, molecular weight is the pure product of complex of the human glucagon-like-peptide-1 (7-37) of 23.355KD.
In above-mentioned second step, molecular weight is mono methoxy polyethylene glycol-propanoic acid butanimide of 20KD, and promptly the addition of mPEG-SPA can be respectively 30.0mg and 60.0mg; In above-mentioned the 6th step, can obtain respectively 2.1 and the molecular weight of 1.4mg be the pure product of complex of the human glucagon-like-peptide-1 (7-37) of 23.355KD.
In the first step, with human glucagon-like-peptide-1 (7-36) NH
2Replace human glucagon-like-peptide-1 (7-37), also can obtain being similar to the result in above-mentioned the 6th step.
The preparation of embodiment 4 human glucagon-like-peptide-1s.In the present embodiment, through the mono methoxy polyethylene glycol of the activatory active group of butanimide for dividing a dendritic mono methoxy polyethylene glycol-succinimide ester, i.e. mPEG-NHS, its molecular weight is 40KD.
The first step is dissolved in the 100mM of 0.5ml with 1.0mg human glucagon-like-peptide-1 (7-37), and is in the pH7.4 phosphate buffer, mixed with 200mM phosphate buffer or the boric acid-borate buffer solution of the pH8.4 of 0.5ml again;
In second step, adding the 11.9mg molecular weight in the solution of the first step is the dendritic mono methoxy polyethylene glycol-succinimide ester of branch of 40KD, and promptly mPEG-NHS is evenly mixed;
The 3rd step to the 5th step is undertaken by cycle and taking corresponding operation among the embodiment one.
The 6th step, with the 5th elute soln molecular cut off collected of step is that the MilliporeAmicon Ultra-15 ultrafiltration pipe of 1～5KD is concentrated, lyophilization, obtain 1.3mg, molecular weight is the pure product of complex of the human glucagon-like-peptide-1 (7-37) of 43.355KD.
In above-mentioned second step, molecular weight is the dendritic mono methoxy polyethylene glycol-succinimide ester of the branch of 40KD, and promptly the addition of mPEG-NHS can be respectively 59.5mg and 119.0mg; In above-mentioned the 6th step, can obtain respectively 3.9 and the molecular weight of 2.6mg be the pure product of complex of the human glucagon-like-peptide-1 (7-37) of 43.355KD.
In the first step, with human glucagon-like-peptide-1 (7-36) NH
2Replace human glucagon-like-peptide-1 (7-37), also can obtain being similar to the result in above-mentioned the 6th step.
The hypoglycemic activity of embodiment 5 human glucagon-like-peptide-1 complex.
Experiment material and method:
Male and healthy kunming mice (cleaning level, Fudan University in Shanghai medical college animal center provides);
50% glucose solution, 0.9%NaCl solution, GLP-1 (7-37);
Blood glucose monitoring system (the newly upright medical apparatus and instruments company limited in Shanghai);
Male and healthy kunming mice overnight fasting is divided into 4 groups, 6 every group.The 1st group, the normal saline matched group; The 2nd group, the glucose matched group; The 3rd group, GLP-1 (7-37) administration group; The 4th group, mPEG-GLP-1 (7-37) administration group, described mPEG-GLP-1 (7-37) is the preparation product of embodiment 1.
The 1st group of lumbar injection 100ul normal saline; The 2nd group of lumbar injection 100ul 50% glucose solution; The GLP-1 (7-37) of the 3rd group of lumbar injection 100ul 50% glucose solution and 0.4ug; The mPEG-GLP-1 (7-37) of the 4th group of lumbar injection 100ul 50% glucose solution and 1ug.Note was zero moment at this moment.Carried out mouse tail vein respectively at 10,30,60,90,120,150,180,210,240 minutes and get blood 10ul, measure blood sugar concentration with blood glucose monitoring system.Be long-time mPEG-GLP-1 (7-37) hypoglycemic activity of observing, the mice of the 2nd group, the 3rd group and the 4th group gives 50ul 50% glucose solution after 60,150 minutes tail veins are got blood immediately once more, only inject the 50ul normal saline for the 1st group, by identical time interval determination blood glucose.
The result as shown in Figure 4, shown in numerical value be the blood glucose meansigma methodss of 6 mices.Compare with the glucose group mice, within after the administration 60 minutes, GLP-1 (7-37) administration group and mPEG-GLP-1 (7-37) administration group all can reduce mouse blood sugar, illustrate that mPEG-GLP-1 (7-37) complex of preparing by the inventive method has kept the biologic activity of GLP-1 (7-37).After 90 minutes, the blood glucose value of GLP-1 (7-37) group mice and glucose group mice is as broad as long, and prompting GLP-1 (7-37) metabolism is intact, no longer has hypoglycemic activity.And the mouse blood sugar of mPEG-GLP-1 (7-37) administration group is lower than glucose group always, and kept stable, illustrates that the half-life of mPEG-GLP-1 (7-37) prolongs, still blood sugar control concentration effectively.
The also prepared product of embodiment 2 to embodiment 4 of used mPEG-GLP-1 (7-37) in the present embodiment.They carry out determination of activity according to the method for present embodiment, have all obtained similar experimental result.
Also human glucagon-like-peptide-1 (7-36) NH of used human glucagon-like-peptide-1 in the present embodiment
2, carry out determination of activity according to the method for present embodiment, all obtained similar experimental result.
Claims (3)
1. the complex of a human glucagon-like-peptide-1 is characterized in that, the human glucagon-like-peptide-1 in this complex refers to human glucagon-like-peptide-1 (7-37) or human glucagon-like-peptide-1 (7-36) NH
2This complex by human glucagon-like-peptide-1 with contain mono methoxy polyethylene glycol through the activatory active group of butanimide: mono methoxy polyethylene glycol-propanoic acid butanimide, be mPEG-SPA or divide dendritic mono methoxy polyethylene glycol-succinimide ester, be that mPEG-NHS forms, both link together by the former aminoacid free amine group and the amido link that forms of the latter's butanimide ester bond, and described mono methoxy polyethylene glycol molecular weight is 5～40KD.
2. the preparation method of the complex of the described human glucagon-like-peptide-1 of claim 1 is characterized in that, the concrete operations step is as follows:
The first step, the human glucagon-like-peptide-1 of 1 part of weight is dissolved in the 100mM of 500 parts of weight, in the pH7.4 phosphate buffer, again with the 200mM of 500 parts of weight, pH6.0～9.0 phosphate buffers or boric acid-borate buffer solution are mixed, and human glucagon-like-peptide-1 is human glucagon-like-peptide-1 (7-37);
Second step, the mono methoxy polyethylene glycol of containing that in the solution of the first step, adds 1.5～119.0 parts of weight through the activatory active group of butanimide, evenly mixed, described mono methoxy polyethylene glycol is that molecular weight is mono methoxy polyethylene glycol-propanoic acid butanimide of 5～40KD, be mPEG-SPA or divide dendritic mono methoxy polyethylene glycol-succinimide ester, i.e. mPEG-NHS;
The 3rd goes on foot, and second solution that goes on foot is placed carried out the mPEG modification reaction under 4～40 ℃ 0.5～24 hour;
The 4th step will place-20 ℃ of cessation reactions through the solution that the 3rd step handled, and so far, make the complex crude product solution of human glucagon-like-peptide-1;
The 5th step, the 4th crude product solution 20mM that make of step learns from else's experience, the acetic acid of pH4.2-sodium-acetate buffer dilutes 10 times, last Sepharose FF CM chromatographic column, with the 20mM that contains 0～1MNaCl, pH4.2 acetic acid-sodium-acetate buffer carries out gradient elution, and flow velocity is 0.1～1ml/min, is the elute soln that the absworption peak in centre in 3 absworption peaks is collected at the 280nm place at wavelength;
The 6th step, with the 5th elute soln molecular cut off collected of step is that the MilliporeAmicon Ultra-15 ultrafiltration pipe of 1～5KD is concentrated, lyophilization, obtain the product of 0.2～3.9 part of weight, be the pure product of complex of human glucagon-like-peptide-1, the molecular weight of described product is between 8.355～43.355KD.
3. the preparation method of the complex of human glucagon-like-peptide-1 according to claim 2 is characterized in that, in the first step, human glucagon-like-peptide-1 is human glucagon-like-peptide-1 (7-36) NH
2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100668974A CN100344323C (en) | 2004-09-30 | 2004-09-30 | Human glucagon-like peptide-1 compound and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100668974A CN100344323C (en) | 2004-09-30 | 2004-09-30 | Human glucagon-like peptide-1 compound and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1676163A true CN1676163A (en) | 2005-10-05 |
| CN100344323C CN100344323C (en) | 2007-10-24 |
Family
ID=35049014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100668974A Expired - Fee Related CN100344323C (en) | 2004-09-30 | 2004-09-30 | Human glucagon-like peptide-1 compound and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100344323C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102363633A (en) * | 2011-11-16 | 2012-02-29 | 天津拓飞生物科技有限公司 | Glucagon like peptide-1 mutant polypeptide and preparation method, medicinal composition and use thereof |
| CN101125207B (en) * | 2006-11-14 | 2012-09-05 | 上海华谊生物技术有限公司 | Exendin or its analogs with polyethylene group and its preparation and application |
| WO2012155780A1 (en) * | 2011-05-19 | 2012-11-22 | 江苏豪森药业股份有限公司 | Branched-peg modified glp-1 analogue and pharmaceutically acceptable salts thereof |
| CN103724424A (en) * | 2013-12-27 | 2014-04-16 | 浙江省农业科学院 | mPEG-SPA-pGLP-2 compound as well as preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| CN1289066C (en) * | 2003-09-18 | 2006-12-13 | 中国人民解放军第二军医大学 | Glicetin -1 slow release microspheric preparation and its use |
-
2004
- 2004-09-30 CN CNB2004100668974A patent/CN100344323C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125207B (en) * | 2006-11-14 | 2012-09-05 | 上海华谊生物技术有限公司 | Exendin or its analogs with polyethylene group and its preparation and application |
| CN102827284A (en) * | 2006-11-14 | 2012-12-19 | 上海华谊生物技术有限公司 | Exendin or analogue containing polyethylene glycol group and preparation and application thereof |
| CN102827284B (en) * | 2006-11-14 | 2015-07-29 | 上海仁会生物制药股份有限公司 | With the Exendin of polyethylene group or its analogue and preparation thereof and purposes |
| US9175060B2 (en) | 2006-11-14 | 2015-11-03 | Shanghai Benemae Pharmaceutical Corporation | PEG modified exendin or exendin analog and compositions and use thereof |
| WO2012155780A1 (en) * | 2011-05-19 | 2012-11-22 | 江苏豪森药业股份有限公司 | Branched-peg modified glp-1 analogue and pharmaceutically acceptable salts thereof |
| CN102363633A (en) * | 2011-11-16 | 2012-02-29 | 天津拓飞生物科技有限公司 | Glucagon like peptide-1 mutant polypeptide and preparation method, medicinal composition and use thereof |
| CN102363633B (en) * | 2011-11-16 | 2013-11-20 | 天津拓飞生物科技有限公司 | Glucagon like peptide-1 mutant polypeptide and preparation method, medicinal composition and use thereof |
| CN103724424A (en) * | 2013-12-27 | 2014-04-16 | 浙江省农业科学院 | mPEG-SPA-pGLP-2 compound as well as preparation method and application thereof |
| CN103724424B (en) * | 2013-12-27 | 2015-05-27 | 浙江省农业科学院 | mPEG-SPA-pGLP-2 compound as well as preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100344323C (en) | 2007-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101125207B (en) | Exendin or its analogs with polyethylene group and its preparation and application | |
| CN101993485B (en) | Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof | |
| CN102234310B (en) | Polyethylene glycol modified protein separating and purifying method | |
| CN101525386B (en) | Fusion protein of Exendin-4 tandem polypeptide and human serum albumin, preparation and application thereof | |
| CN108640985A (en) | A method of purifying Suo Malu peptides | |
| CN102026666A (en) | Formulation of insulinotropic peptide conjugates | |
| CN102010473A (en) | Recombinant oxyntomodulin (OXM) fusion protein, and preparation and application thereof | |
| CN100344323C (en) | Human glucagon-like peptide-1 compound and its preparing method | |
| CN1982336B (en) | Human pancreas glucagon sample peptide-1-derivative, its production and use | |
| CN102532303A (en) | Synthesis and application of exenatide joined with polyethylene glycol | |
| CN1817904A (en) | Gerobriecin pancrease glucagon peptidel (SGLP-1), its preparation and use | |
| CN103275209A (en) | Liraglutide preparation method | |
| CN1651463A (en) | Mono methoxy polyethylene glycol-insulin complex substance and its preparation method | |
| CN106279430B (en) | Analog fusions of Exendin 4 and its production and use | |
| CN1587385A (en) | High efficiency experssino human glicentin-1 gene engineering bacteria and its construction method and use | |
| CN103333238A (en) | mPEG-MAL-aGLP-1 composite | |
| WO2020087947A1 (en) | Method for modification of polypetide and uses | |
| CN102234331A (en) | Composition of Exendin-4 derivative and preparation method and application thereof | |
| CN1861635A (en) | Human pancreas hyperglycemiacin relative peptide-2 analogue | |
| CN102212127A (en) | Glucagon-like peptide-2 poly(ethylene glycol) conjugate, and preparation method and application thereof | |
| CN1634993A (en) | Recombined human interferon-alpha 1b compound and process for preparation | |
| CN1338463A (en) | Method for improving stability of polypeptide in body and its application | |
| CN101962652A (en) | Complex of human glucagon-like peptide (GLP)-1 and preparation method thereof | |
| CN101376676A (en) | PEGylated erythropoietin protein long-acting preparation | |
| CN104945498A (en) | Preparation for long-acting PEG-rExendin-4 modified body coupling product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071024 Termination date: 20150930 |
|
| EXPY | Termination of patent right or utility model |